Prof. Yang Huijuan of Fudan University Shanghai Cancer Center detailed the findings from a Phase I/II trial involving 55 patients with recurrent or metastatic cervical cancer. Among those evaluable for efficacy, the confirmed objective response rate reached 32.08%, with a disease control rate of 81.13%. Patients previously treated with immune checkpoint inhibitors saw a median progression-free survival of 4.0 months, while median overall survival had not yet been reached at the time of the data cut-off.
Mabwell Reports Promising Clinical Results for Nectin-4 ADC 9MW2821
At the 2026 ESMO Gynaecological Cancers Congress in Copenhagen, Mabwell presented new clinical data for 9MW2821, a Nectin-4-targeting antibody-drug conjugate. The study highlighted the drug’s efficacy in treating advanced cervical cancer, showing notable survival benefits for patients previously treated with immunotherapy.
A separate study evaluated 9MW2821 in combination with the PD-1 inhibitor toripalimab. Preliminary data from 19 patients showed an objective response rate of 76.9%, climbing to 80% among treatment-naïve patients. The combination therapy demonstrated a manageable safety profile, with most adverse events categorized as Grade 1 or 2, suggesting a potential path forward for first-line treatment protocols in cervical cancer care.
Comments (0)
No comments yet. Be the first!